Weight loss Tablets

Eli Lilly: A New Leader Is Coming

Could the long-running obesity drugs leadershipanchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli Lilly and Company (LLY)spent most of the past two years innovating and catching up with the NVO’s dominance, it still wasn’t sufficient to surpass the Danish biopharma company.

Although there’s little doubt that both companies are still projected to dominate the massive obesity drugs market, rivals are committing to invest and attempt to erode these advantages, whether through internal pipeline innovation, or through M&A targets to incorporate capabilities to take on Novo Nordisk and Eli Lilly.

Hence, it’s imperative that Lilly demonstrate remarkable results on its next-gen product in its obesity drugs portfolio through Orforglipron. The Phase III results for its oral weight loss pill has validated the market’s confidence in LLY, showing why NVO has underperformed LLY since mid-2024.

The average 7.9% in weight loss exhibits superior results as compared to some results “in earlier studies of Ozempic.” In addition, the company also shared that study participants have not yet reached a “weight plateau,” auguring well for further potential weight reduction in further comparisons.